Form 13-F position report

CUE BIOPHARMA INC

Reported by MORGAN STANLEY

CUE CUSIP 22978P106 Manager CIK 0000895421

Reported 198,579 shares, up 21,940 (12.4%) from the prior quarter.

Reported value -51.5%; share count 12.4% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q1 2022
Shares 198,579 Quarter-end amount reported
Reported value $969,000 Fair value at quarter end
Consecutive quarters held 17 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 6909000
2021-12-31 1998000
2022-03-31 969000
2022-06-30 1084000
2022-09-30 569000
2022-12-31 509570
2023-03-31 353162
2023-06-30 386218
2023-09-30 286437
2023-12-31 434824
2024-03-31 283266
2024-06-30 150039
2024-09-30 25511
2024-12-31 31276
2025-03-31 26138
2025-06-30 20095
2025-09-30 19772
2025-12-31 5679
2026-03-31 4224
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for CUE BIOPHARMA INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -18,374 (-100.0%) 0 $0 2026-08-13
Q1 2026 Reduced 18,374 -220 (-1.2%) < 0.01% $4,224 2026-05-15
Q4 2025 Reduced 18,594 -8,917 (-32.4%) < 0.01% $5,679 2026-02-13
Q3 2025 Reduced 27,511 -1,940 (-6.6%) < 0.01% $19,772 2025-11-14
Q2 2025 Added 29,451 +760 (2.6%) < 0.01% $20,095 2025-08-15
Q1 2025 Reduced 28,691 -2 (0.0%) < 0.01% $26,138 2025-05-15
Q4 2024 Reduced 28,693 -4,998 (-14.8%) < 0.01% $31,276 2025-02-14
Q3 2024 Reduced 33,691 -87,308 (-72.2%) < 0.01% $25,511 2024-11-14
Q2 2024 Reduced 120,999 -28,877 (-19.3%) < 0.01% $150,039 2024-08-14
Q1 2024 Reduced 149,876 -14,830 (-9.0%) < 0.01% $283,266 2024-05-15
Q4 2023 Added 164,706 +40,168 (32.3%) < 0.01% $434,824 2024-02-13
Q3 2023 Added 124,538 +18,725 (17.7%) < 0.01% $286,437 2023-11-15
Q2 2023 Added 105,813 +6,888 (7.0%) < 0.01% $386,218 2023-08-14
Q1 2023 Reduced 98,925 -79,871 (-44.7%) < 0.01% $353,162 2023-05-15
Q4 2022 Reduced 178,796 -76,512 (-30.0%) < 0.01% $509,570 2023-02-14
Q3 2022 Reduced 255,308 -179,700 (-41.3%) < 0.01% $569,000 2022-11-14
Q2 2022 Added 435,008 +236,429 (119.1%) < 0.01% $1,084,000 2022-08-15
Q1 2022 Added 198,579 +21,940 (12.4%) < 0.01% $969,000 2022-05-13
Q4 2021 Reduced 176,639 -297,494 (-62.7%) < 0.01% $1,998,000 2022-02-14
Q3 2021 Added 474,133 +46,905 (11.0%) < 0.01% $6,909,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

109 managers reported CUE BIOPHARMA INC for Q1 2022.

Managers reporting CUE BIOPHARMA INC in Q1 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 2,381,267 +90,998 < 0.01% $11,622,000 17 qtrs
Nantahala Capital Management LLC Reduced 2,244,359 -295,341 0.48% $10,952,000 16 qtrs
VANGUARD GROUP INC Added 1,653,737 +102,423 < 0.01% $8,070,000 17 qtrs
Prosight Management LP Added 1,510,282 +681,240 4.76% $7,370,000 10 qtrs
Slate Path Capital LP Unchanged 1,483,619 0 0.37% $7,240,000 11 qtrs
SANDERS MORRIS HARRIS LLC Added 873,021 +513,908 0.83% $4,261,000 7 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 741,903 -107,440 < 0.01% $3,620,000 4 qtrs
STATE STREET CORPORATION Reduced 727,023 -935,229 < 0.01% $3,548,000 17 qtrs
Bleichroeder LP Added 552,000 +352,000 0.48% $2,694,000 10 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 548,405 +27,001 < 0.01% $2,676,000 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 13, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
98,760
Shared
574
None
99,245

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.